New antibody therapy tested for Hard-to-Treat lupus
NCT ID NCT05796206
Summary
This study is testing whether a new antibody drug called MIL62 can help control the symptoms and disease activity of systemic lupus erythematosus (SLE). The trial will compare MIL62 against a placebo in 120 adults with active lupus over 76 weeks. Researchers will measure whether the treatment reduces disease flare-ups and allows patients to lower their steroid doses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.